STOCK TITAN
  1. Home
  2. News
  3. AEZS

Aeterna Zentaris Inc. - AEZS STOCK NEWS

Welcome to our dedicated news page for Aeterna Zentaris (Ticker: AEZS), a resource for investors and traders seeking the latest updates and insights on Aeterna Zentaris.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Aeterna Zentaris's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Aeterna Zentaris's position in the market.

News
Ceapro Receives Final Court Approval for Merger with Aeterna Zentaris
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. have received final court approval for their all-stock merger of equals transaction. The Transaction is expected to be completed in the second quarter of 2024, pending necessary approvals and conditions.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.29%
Tags
acquisition
-
News
Aeterna Zentaris Reports Fourth Quarter and Full Year 2023 Financial Results and Announces Completion of Enrollment in Ongoing Pivotal DETECT-Trial for the Diagnosis of Childhood-Onset Growth Hormone Deficiency
Rhea-AI Summary
Aeterna Zentaris Inc. completes enrollment in pivotal Phase 3 trial, reports $34.0 million cash, and announces merger with Ceapro, Inc. Financial results show a net loss decrease in Q4 2023 compared to 2022.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
earnings
-
News
Aeterna Zentaris and Ceapro Merger Approved by Securityholders at Special Meetings
Rhea-AI Summary
Aeterna Zentaris Inc. and Ceapro Inc. announce the approval of their all-stock merger of equals transaction by securityholders. The voting results show strong support for the merger, with Aeterna shareholders approving the transaction by high percentages. The merger is expected to create a sustainable business for delivering value to the biopharma sector and shareholders. The transaction is subject to customary closing conditions and is expected to close in the second quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.51%
Tags
acquisition
News
Aeterna Zentaris Issues Letter to Shareholders and Management Proxy Circular Ahead of Special Meeting of Shareholders to Approve Merger of Equals with Ceapro
Rhea-AI Summary
Aeterna Zentaris Inc. recommends shareholders vote for the merger with Ceapro Inc. to create a diversified biopharmaceutical company. The merger aims to combine Ceapro's revenue-generating cosmeceutical business with Aeterna's pipeline of higher-margin pharmaceutical products, potentially leading to stable cash flow, diversified product pipeline, and expanded R&D capabilities. The merger is expected to provide a compelling value proposition and lower risk profile for the combined company and shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.15%
Tags
acquisition
-
News
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create a Diversified Biopharmaceutical Company
Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) and Ceapro Inc. (TSXV: CZO) (OTCQX: CRPOF) have announced a definitive agreement to combine operations in an all-stock merger of equals transaction. The combined company is expected to be listed on the Nasdaq Capital Market and the Toronto Stock Exchange, creating a long-term sustainable business optimally positioned to deliver value as the biopharma sector recovers. Shareholders of each company will share in future value creation, with existing securityholders of Aeterna and Ceapro to each own 50% of the combined company, respectively. The transaction is expected to close in the first quarter of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
acquisition
-
News
Aeterna Zentaris Reports Third Quarter 2023 Financial Results
Rhea-AI Summary
Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) reported the launch of Ghryvelin™ in key European countries, approval of Macrilen® in South Korea, and ended the quarter with $38.8 million in cash, projecting funding into 2025. The company's financial results for the quarter ended September 30, 2023, show a net loss of $4.1 million and a revenue decrease of $1.9 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.67%
Tags
earnings
News
Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference
Rhea-AI Summary
Aeterna Zentaris Inc. announced that its CEO, Dr. Klaus Paulini, will participate in the Virtual Investor Ask the CEO Conference on October 25th. Investors can submit questions live or pre-submit them through the event's website. The presentation will be available for replay on the company's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
News
Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Rhea-AI Summary
Aeterna Zentaris CEO to present at H.C. Wainwright conference, focusing on AIM Biologicals development programs for NMOSD and PD.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.38%
Tags
conferences
-
News
Aeterna Zentaris Reports Second Quarter 2023 Financial Results
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.7%
Tags
earnings
News
Aeterna Zentaris Outlines Progress on Development Pipeline Programs and Provides Corporate Update
Rhea-AI Summary
Aeterna Zentaris Inc. provides an update on its therapeutic and diagnostic development pipeline programs. The company is making progress in patient recruitment for its DETECT clinical trial and expects to complete the study by the end of the year. Aeterna also plans to secure a development and commercialization partner for Macrilen® for the U.S. and Canada. In terms of therapeutics development, the company is focused on autoimmunity modifying fusion proteins for the potential treatment of neuromyelitis optica spectrum disorder and Parkinson's disease. They have received positive feedback from their collaborator and scientific advisor on the NMOSD indication. Aeterna is also working on a potential treatment for chronic hypoparathyroidism and a ghrelin agonist for the treatment of ALS. The company has a strong financial position with cash projected to fund operations and pipeline programs into 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
none
Stock AEZS logo
Aeterna Zentaris Inc.

Nasdaq:AEZS

AEZS Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

AEZS Stock Data

9.51M
4.85M
3.95%
0.8%
0.45%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
United States
Summerville

About AEZS

æterna zentaris inc. (tsx: aez, nasdaq: aezs) is a global biopharmaceutical company focused on endrocrine therapy and oncology, with proven expertise in drug discovery, development and commercialization. æterna zentaris inc. (tsx: aez, nasdaq: aezs) est une société biopharmaceutique internationale, spécialisée dans la découverte, le développement et la commercialisation de thérapies en endocrinologie et en oncologie.